The Institute of Cancer Research, Chester Beatty Laboratories, Targeted Therapy Laboratory, 237 Fulham Road, London SW3 6JB, UK.
Cytokine Growth Factor Rev. 2010 Apr-Jun;21(2-3):91-8. doi: 10.1016/j.cytogfr.2010.02.006. Epub 2010 Mar 12.
It is time for those working on oncolytic viruses to take stock of the status of the field. We now have at our disposal an array of potential therapeutic agents, and are beginning to conduct early-phase clinical trials in patients with relapsed/metastatic cancers. By drawing on lessons learned during the development of other biological therapies, such as monoclonal antibodies and targeted small molecule inhibitors, we are now in a position to chart the course of the next wave of trials that will go beyond the phase I studies of safety and feasibility. In this article we review our approach to the development of oncolytic viruses as cancer therapeutics. In doing so, we emphasise the fact that this process is modular and involves multiple iterative steps between the laboratory and the clinic. Ultimately, at least in the medium term, the future of oncolytic virotherapy lies in combination regimens with standard anti-cancer agents such as radiation and chemotherapy.
是时候让从事溶瘤病毒研究的人员评估一下该领域的现状了。我们现在有一系列潜在的治疗药物，并开始在复发性/转移性癌症患者中进行早期临床试验。通过借鉴其他生物疗法（如单克隆抗体和靶向小分子抑制剂）开发过程中的经验教训，我们现在可以规划下一阶段的试验，这些试验将超越安全性和可行性的 I 期研究。在本文中，我们回顾了将溶瘤病毒作为癌症治疗药物开发的方法。在这样做的过程中，我们强调了一个事实，即这个过程是模块化的，并且在实验室和临床之间涉及多个迭代步骤。最终，至少在中期内，溶瘤病毒治疗的未来在于与标准抗癌药物（如放疗和化疗）联合治疗方案。
